US judge upholds Lilly's Gemzar compound patent, but second patent an issue
This article was originally published in Scrip
Executive Summary
A federal judge in Indiana has upheld the main compound patent protecting Lilly's chemotherapy drug Gemzar (gemcitabine HCl for injection) which blocks Teva Pharmaceutical Industries from introducing in the US its own version until Lilly's US exclusivity (which includes a paediatric exclusivity) for the product expires on 15 November 2010, but the drug still faces another challenge in a separate court.